H.-P. Xu

Final Analysis of the Neotorch Study: Perioperative Toripalimab in Combination with Chemotherapy for Patients with Stage Ⅱ/Ⅲ Resectable Non-Small Cell Lung Cancer.

BACKGROUND Interim analysis of the Neotorch study demonstrated significant benefit in event-free survival (EFS) and major pathological response (MPR) rate for perioperative toripalimab plus chemotherapy in patients with resectable Stage Ⅲ non-small cell lung cancer (NSCLC). Here, we report the final analysis results of...

[Diagnostic value of multi-parameter combined detection for severe fever with thrombocytopenia syndrome virus infection].